Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
You must be a Standard 1 Year member to access this content.
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Scholar Rock Holding Corporation on the deal. Scholar Rock Holding Corporation announced the completion of its registered direct offering of 16,326,530 shares of common...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
You must be a Standard 1 Year member to access this content.
Fox Rothschild LLP advised PharmaCann on the deal. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and PharmaCann Inc. (“PharmaCann”), one of the largest vertically integrated cannabis companies...
You must be a Standard 1 Year member to access this content.
